De novo AML patients with favourable-intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened "GO question".

Clavio M;Cruciani F;Minetto P;Guolo F;Ballerini F;Marani C;De Astis E;Aquino S;Bergamaschi M;Mitscheunig L;Grasso R;Colombo N;Ghiggi C;Lovera D;Pastori G;Avenoso D;MIGLINO, MAURIZIO;GOBBI, MARCO

2013-01-01